icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Boston MA
November 2019
Back grey_arrow_rt.gif
 
 
 
PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study
 
 
  AASLD Boston, Massachusetts November 8-11 2019
 
Neeta B. Amin*, Santos Carvajal-Gonzalez*, Naresh Aggarwal, Theresa A. Tuthill*, Malgorzata Inglot, Arthur Bergman*, William Esler* *Pfizer Inc. employees

1205191

1205192

1205193

1205194

1205195

1205196

1205197

1205198

1205199